Assessing Environmental Impact of Biopharmaceutical Manufacturing

Consistent with the overall industry trend to reduce environmental impact in manufacturing operations, GSK’s Biopharmaceutical Product Development and Supply team have implemented sustainability initiatives to assess the environmental impact of biopharm manufacturing. Mr. Alexander Adams, from GlaxoSmithKline, will present how impact assessment during the clinical development of product and process lifecycle provides the best opportunity for reducing carbon footprint of a commercialized product. He will describe the assessment tools used by GSK and their relative strengths and weaknesses for assessing environmental impact. Additionally, Mr. Adams will share conclusions on the opportunistic areas for all biopharmaceutical manufacturers to consider when assessing and reducing the environmental impact of their manufacturing activities.


Alexander Adams

Alexander Adams

Project Engineer, Biopharmaceutical Product Development & Supply at GlaxoSmithKline

Alex has worked in regulated manufacturing facilities across multiple industries and is passionate about sustainability and he brings that perspective as he advances improvements for traditional objectives in manufacturing quality, throughput and safety. Over the past few years at GSK, he has worked with a team of scientists and engineers on the development and maintenance of a series of sustainability metrics for the manufacturing facility and its various production processes. These metrics are designed to drive improvements in facility design and encourage sustainable process development. Alex received a B.S. in both Mechanical and Biomedical Engineering from Boston University and recently completed his MBA at Lehigh University. 

Registration Information:



ISPE Members




Emerging Leaders/Student


Group/Multiple Participants (in one sitting) $50

Register Now!

**Participants can earn 1 PDH credit for attending**